SCHEMBL1474910

SCHEMBL1474910

CC(=O)Nc1ccc(OCc2cccc(-c3ccc4nc(-c5ccc(C)cc5)cn4c3)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.60
KDM4E B2RXH2 8/20 0.60
NPC1 O15118 7/20 0.60
RAB9A P51151 7/20 0.60
SMN1; SMN2 Q16637 6/20 0.60
HPGD P15428 6/20 0.60
POLB P06746 1/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
NR4A2 P43354 2/20 0.48
CYP2C9 P11712 1/20 0.48
KCNH2 Q12809 1/20 0.48
FFAR1 O14842 5/20 0.48
JAK2 O60674 1/20 0.47
JAK3 P52333 1/20 0.47
ALDH1A3 P47895 2/20 0.47
SLC2A1 P11166 1/20 0.47
KMT2A Q03164 1/20 0.46
ADRB2 P07550 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1474716 0.88 ALDH1A3 (0.59) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL1472990 0.88 MAOB (0.55) ALDH1A1KDM4ENPC1RAB9APOLB
SCHEMBL1472663 0.84 NR4A2 (0.66) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL1472923 0.82 ALDH1A3 (0.58) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL1474701 0.81 FFAR1 (0.51) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL1474690 0.77 RAB9A (0.54) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL1472658 0.76 NR4A2 (0.80) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL1472245 0.72 NR4A2 (0.73) ALDH1A1KDM4ENPC1RAB9AHPGD
SCHEMBL10599882 0.71 MEN1 (0.70) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4726593 0.70 ALDH1A1 (0.74) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915284-B2 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-29 US claimed
EP-2069342-B1 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-05-12 EP claimed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US claimed
US-7915284-B2 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-29 US disclosed
EP-2069342-B1 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-05-12 EP disclosed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF NCOR1, NR4A2, NR4A3 ALDH1A1 1788/4885KDM4E 2549/4885NPC1 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.